MBX Biosciences, Inc. (MBX)

MBX Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-77.02	-61.92	-32.56	-26.14
Depreciation & Amortization	0.27	0.24	0.16	0.06
Loss (Gain) From Sale of Assets	-	-	0.07	-
Loss (Gain) From Sale of Investments	-4.31	-2.93	-1.04	-0.03
Stock-Based Compensation	6.46	5.22	2.04	0.31
Other Operating Activities	0.12	0.11	0.1	1.39
Change in Accounts Payable	3.32	3.93	0.41	0.67
Change in Other Net Operating Assets	0.34	0.67	-1.15	0.62
Operating Cash Flow	-70.81	-54.68	-31.98	-23.12
Capital Expenditures	-0.89	-0.87	-0.13	-0.44
Investment in Securities	-138.04	-159.72	-30.8	-10.97
Investing Cash Flow	-138.92	-160.6	-30.93	-11.41
Short-Term Debt Issued	-	-	-	10
Total Debt Issued	-	-	-	10
Net Debt Issued (Repaid)	-	-	-	10
Issuance of Common Stock	176.04	174.95	0.74	0.03
Other Financing Activities	-2.52	-4.34	-0.03	-0.46
Financing Cash Flow	237.01	234.1	69.22	46.06
Net Cash Flow	27.28	18.83	6.31	11.53
Free Cash Flow	-71.7	-55.56	-32.11	-23.56
Free Cash Flow Per Share	-2.68	-5.22	-31.52	-35.33
Levered Free Cash Flow	-45.42	-33.27	-20.56	-
Unlevered Free Cash Flow	-45.42	-33.27	-20.56	-
Change in Working Capital	3.66	4.6	-0.74	1.29

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q